CN

2021

New drug approval license of Mitoxantrone hydrochloride injection for tracing;
Gosun's cefazolin and ceftazidime for injection won bidding in National centralized procurement;

Gosun's production lines re-certificated by EU GMP.

1991

Started the construction of the first manufacture factory for Gosun.

1992

Gosun's synthesis workshop was completed and put into production.

1993

Became Provincial GMP system pilot enterprise during the first implement of GMP system in China;
Marked the turning point of Gosun's quality system.

1994-
1998

Ushered in the climax of development in the cephalosporin antibiotic market,
Gosun's products accounted for a large share of the domestic market,
The sales of major varieties such as ceftriaxone and cefotaxime were among the top.

2001

Joining hands with the China National Inspection Institute,
improved the chemical structure of cefazolin sodium, which results a large clinical effect benifits. 
The patented new drug cefazolin sodium pentahydrate (trade name: Xintailin®) was born.

2006

Xintailin® successfully launched as a new drug for its structural
technological innovation, and obtained 20-years patents
for both its structure and unique crystal form.
The drug became a blockbuster in China market afterwards.

2008

Gosun was recognized as a national high-tech enterprise for the first time.

2009

Gosun business both in domestic and overseas were boosting;
Shenyang Sanjiu factory started construction for the boosting business;
Gosun started EU certification project for powder injection workshop.

2010
Powder injection workshop obtained EU cGMP certification

Shenyang Sanjiu factory was completed and put into production;

Xintailin became the top product of domestic antibiotic products.

2012
The synthesis workshop obtained EU cGMP certification;
Became a manufacturer with a full range of EU certification
for API and finished products.
2013

Become the Rochefin CMO strategic partner for Roche,
Started the long-term partnership.

2014

CR Gosun became the anti-infective division of CR Sanjiu;
New HQ building started construction;
CR Gosun entered a new and high-speed development era.

2015

Acquired Zhejiang Zhongyi and enrich Gosun's product list to oral products.

2016
Xintailin® won the second National Prize of Progress in Science and Technology Award;
Gosun's workshops passed EU GMP re-certification;
Gosun won China Resources Group's Best Innovation Gold Award.
2017

License-in Ceftobiprole Medocaril Sodium for Injection from Basilea;
Co-develop Mitoxantrone Hydrochloride Injection for Tracing with SPU;
Awarded by the enterprise workstations of academicians and experts (provincial and municipal levels)


2018

Founded a sales&marketing platform: China Resources Jiuzhong;
Founded an innovative drug incubation platform: China Resources Jiuchuang;
Gosun began to explore the perioperative treatment to pave the way for innovation and transformation.

2019
Became Roche's world's first monoclonal antibody biologics strategic partner,became Roche's world's first monoclonal antibody biologics strategic partner, marking the company's entry into a brand new international development pathway.
2020
Ceftobiprole Medocaril Sodium for Injection
Obtained the Drug Approval License by NMPA (the first fifth-generation cephalosporin antibiotic approved in China)